Physician profile
Kellie Bagi
NPI 1093368631
$14,409.35
in general payments reported to CMS, 2019-2025
47 companies · $1,835 in 2025
The $1,835 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,627 · 2022: $3,674 · 2023: $3,487 · 2024: $2,786 · 2025: $1,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,107.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,628.55 | 2021-2025 | |
| Amgen INC. | $1,145.66 | 2021-2025 | Uplizna, Aimovig |
| Boston Scientific Corporation | $1,053.89 | 2023-2025 | Infinion 16, Infinion 16, Artisan |
| Neurocrine Biosciences, INC. | $932.26 | 2022-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $705.30 | 2022-2025 | |
| Ucb, INC. | $682.03 | 2021-2025 | Briviact |
| Pfizer INC. | $608.78 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $512.38 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $511.49 | 2021-2024 | Austedo Xr, Austedo, Ajovy |
| Lilly USA, LLC | $435.32 | 2021-2024 | Amyvid, Emgality, Kisunla |
| Jazz Pharmaceuticals INC. | $422.27 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $385.13 | 2022 | |
| Genentech USA, INC. | $365.74 | 2022-2024 | Ocrevus, Ocrevus Zunovo |
| Argenx US, INC. | $339.22 | 2022-2025 | Vyvgart |
| Janssen Pharmaceuticals, INC | $288.44 | 2021-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Bagi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.